Abdelnabi R, Foo CS, Kaptein SJF, et al (2021) The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. bioRxiv 2020.12.10.419242
Agostini ML, Pruijssers AJ, Chappell JD et al (2019) Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 93:e013148-19
Article
Google Scholar
Ali I, Alharbi OML (2020) COVID-19: disease, management, treatment, and social impact. Sci Total Environ 728:138861. https://doi.org/10.1016/j.scitotenv.2020.138861
Article
CAS
PubMed
PubMed Central
ADS
Google Scholar
Amann K, Boor P, Wiech T et al (2021) COVID-19 effects on the kidney. Pathologe 42:183–187. https://doi.org/10.1007/s00292-020-00899-1
Article
CAS
PubMed
PubMed Central
Google Scholar
Azer SA (2020) COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect 37:100738. https://doi.org/10.1016/j.nmni.2020.100738
Article
CAS
PubMed
PubMed Central
Google Scholar
Benny R, Khadilkar S (2020) COVID-19: Neuromuscular manifestations. Ann Indian Acad Neurol. https://doi.org/10.4103/aian.AIAN_614_20
Article
PubMed
PubMed Central
Google Scholar
Cascella M, Rajnik M, Aleem A, et al (2021) Features, evaluation, and treatment of coronavirus (COVID-19). Treasure Island (FL)
Chakraborty I, Maity P (2020) COVID-19 outbreak: migration, effects on society, global environment and prevention. Sci Total Environ 728:138882. https://doi.org/10.1016/j.scitotenv.2020.138882
Article
CAS
PubMed
ADS
Google Scholar
Costantini VP, Whitaker T, Barclay L et al (2012) Antiviral activity of nucleoside analogues against norovirus. Antivir Ther 17:981–991. https://doi.org/10.3851/IMP2229
Article
CAS
PubMed
PubMed Central
Google Scholar
Cox RM, Wolf JD, Plemper RK (2021) Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 6:11–18. https://doi.org/10.1038/s41564-020-00835-2
Article
CAS
PubMed
Google Scholar
Cui J, Li F, Shi Z-L (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192
Article
CAS
PubMed
Google Scholar
Ehteshami M, Tao S, Zandi K et al (2017) Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. Antimicrob Agents Chemother 61:e02395-16
Article
PubMed
PubMed Central
Google Scholar
Emani VR, Goswami S, Nandanoor D et al (2021) Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. Int J Antimicrob Agents 57:106222. https://doi.org/10.1016/j.ijantimicag.2020.106222
Article
CAS
PubMed
Google Scholar
Ghanbari R, Teimoori A, Sadeghi A et al (2020) Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol 15:1747–1758. https://doi.org/10.2217/fmb-2020-0120
Article
CAS
PubMed
Google Scholar
Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M (2021) Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. https://doi.org/10.1016/j.jbc.2021.100770
Article
PubMed
PubMed Central
Google Scholar
Harapan H, Itoh N, Yufika A et al (2020) Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health 13:667–673. https://doi.org/10.1016/j.jiph.2020.03.019
Article
PubMed
PubMed Central
Google Scholar
Hollecker L, Choo H, Chong Y et al (2004) Synthesis of β-enantiomers of N4-hydroxy-3′ -deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture. Antivir Chem Chemother 15:43–55. https://doi.org/10.1177/095632020401500105
Article
CAS
PubMed
Google Scholar
Huchting J (2020) Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. Antivir Chem Chemother 28:2040206620976786. https://doi.org/10.1177/2040206620976786
Article
CAS
PubMed
PubMed Central
Google Scholar
Humeniuk R, Mathias A, Cao H et al (2020) Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci 13:896–906
CAS
PubMed
PubMed Central
Google Scholar
Iadecola C, Anrather J, Kamel H (2020) Effects of COVID-19 on the nervous system. Cell 183:16-27.e1. https://doi.org/10.1016/j.cell.2020.08.028
Article
CAS
PubMed
PubMed Central
Google Scholar
Jayk Bernal A, Gomes da Silva MM, Musungaie DB et al (2021) Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. https://doi.org/10.1056/nejmoa2116044
Article
PubMed
PubMed Central
Google Scholar
Jean S-S, Lee P-I, Hsueh P-R (2020) Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect 53:436–443. https://doi.org/10.1016/j.jmii.2020.03.034
Article
CAS
PubMed
PubMed Central
Google Scholar
Khanna K, Kohli SK, Kaur R et al (2021) Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle. Phytomedicine 85:153361. https://doi.org/10.1016/j.phymed.2020.153361
Article
CAS
PubMed
Google Scholar
Khuroo MS (2020) Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int J Antimicrob Agents 56:106101. https://doi.org/10.1016/j.ijantimicag.2020.106101
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim PS, Read SW, Fauci AS (2020) Therapy for early COVID-19: a critical need. JAMA 324:2149–2150
Article
CAS
PubMed
Google Scholar
Knight TE (2020) Severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019: a clinical overview and primer. Biopreserv Biobank 18:492–502
Article
CAS
PubMed
Google Scholar
Li P, Wang Y, Lavrijsen M et al (2022) SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. https://doi.org/10.1038/s41422-022-00618-w
Article
PubMed
PubMed Central
Google Scholar
Mahase E (2021) Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn. BMJ. https://doi.org/10.1136/bmj.n1077
Article
PubMed
Google Scholar
Mao R, Qiu Y, He J-S et al (2020) Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5:667–678. https://doi.org/10.1016/S2468-1253(20)30126-6
Article
PubMed
PubMed Central
Google Scholar
Martinot M, Jary A, Fafi-Kremer S et al (2020) Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1474
Article
Google Scholar
McAdams M, Ostrosky-Frid M, Rajora N, Hedayati S (2021) Effect of COVID-19 on kidney disease incidence and management. Kidney360 2:141 LP – 153. https://doi.org/10.34067/KID.0006362020
Mestres J (2020) The target landscape of N4-hydroxycytidine based on its chemical neighborhood. bioRxiv
Mishra AK, Sahu KK, George AA, Lal A (2020) A review of cardiac manifestations and predictors of outcome in patients with COVID - 19. Heart Lung 49:848–852. https://doi.org/10.1016/j.hrtlng.2020.04.019
Article
PubMed
PubMed Central
Google Scholar
News GE and B (2021) Merck & Co. (Ridgeback Biotherapeutics) and Drug Innovations at Emory (DRIVE) – MK-4482 (formerly EIDD-2801)
Organization WH (2020a) Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020a. World Health Organization
Organization WH (2020b) Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. In: Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, p 21
Painter GR, Bowen RA, Bluemling GR et al (2019) The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res 171:104597
Article
CAS
PubMed
Google Scholar
Parekh M, Donuru A, Balasubramanya R, Kapur S (2020) Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era. Radiology 297:E289–E302. https://doi.org/10.1148/radiol.2020202504
Article
PubMed
Google Scholar
Popowska E, Janion C (1975) The metabolism of N4-hydroxycytidine-a mutagen for Salmonella typhimurium. Nucleic Acids Res 2:1143–1151. https://doi.org/10.1093/nar/2.7.1143
Article
CAS
PubMed
PubMed Central
Google Scholar
Popowska E, Janion C (1974) N4-hydroxycytidine—a new mutagen of a base analogue type. Biochem Biophys Res Commun 56:459–466. https://doi.org/10.1016/0006-291X(74)90864-X
Article
CAS
PubMed
Google Scholar
Prevention C for DC and (2020) Information for clinicians on therapeutic options for COVID-19 patients. Updat April 13:
Qi Z (2020) Severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. Acad J Second Mil Med Univ
Reynard O, Nguyen X-N, Alazard-Dany N et al (2015) Identification of a new ribonucleoside inhibitor of ebola virus replication. Viruses 7:6233–6240
Article
CAS
PubMed
PubMed Central
Google Scholar
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E et al (2020) Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 34:101623. https://doi.org/10.1016/j.tmaid.2020.101623
Article
PubMed
PubMed Central
Google Scholar
Rosenke K, Hansen F, Schwarz B et al (2021) Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun 12:2295. https://doi.org/10.1038/s41467-021-22580-8
Article
CAS
PubMed
PubMed Central
ADS
Google Scholar
Sahu KK, Lal A, Mishra AK (2020) An update on CT chest findings in coronavirus disease-19 (COVID-19). Heart Lung 49:442–443. https://doi.org/10.1016/j.hrtlng.2020.03.007
Article
PubMed
PubMed Central
Google Scholar
Salganik RI, Vasjunina EA, Poslovina AS, Andreeva IS (1973) Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt−. Mutat Res Mol Mech Mutagen 20:1–5. https://doi.org/10.1016/0027-5107(73)90091-2
Article
CAS
Google Scholar
Schafer A, Cheng H, Lee C et al (2018) Development of potential small molecule therapeutics for treatment of Ebola virus disease. Curr Med Chem 25:5177–5190. https://doi.org/10.2174/0929867324666171010141416
Article
CAS
PubMed
Google Scholar
Sheahan TP, Sims AC, Zhou S et al (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. https://doi.org/10.1126/scitranslmed.abb5883
Article
PubMed
PubMed Central
Google Scholar
Shereen MA, Khan S, Kazmi A et al (2020) COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses. J Adv Res 24:91–98. https://doi.org/10.1016/j.jare.2020.03.005
Article
CAS
PubMed
PubMed Central
Google Scholar
Şimşek Yavuz S, Ünal S (2020) Antiviral treatment of COVID-19. Turk J Med Sci 50:611–619. https://doi.org/10.3906/sag-2004-145
Article
CAS
PubMed
PubMed Central
Google Scholar
Singh AK, Singh A, Singh R, Misra A (2021) Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr Clin Res Rev 15:102329. https://doi.org/10.1016/j.dsx.2021.102329
Article
Google Scholar
Stasi C, Fallani S, Voller F, Silvestri C (2020) Treatment for COVID-19: an overview. Eur J Pharmacol 889:173644. https://doi.org/10.1016/j.ejphar.2020.173644
Article
CAS
PubMed
PubMed Central
Google Scholar
Sticher ZM, Lu G, Mitchell DG et al (2020) Analysis of the potential for N4-hydroxycytidine to inhibit mitochondrial replication and function. Antimicrob Agents Chemother 64:e01719-19
Article
PubMed
PubMed Central
Google Scholar
Stuyver LJ, Whitaker T, McBrayer TR et al (2003) Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47:244–254. https://doi.org/10.1128/aac.47.1.244-254.2003
Article
CAS
PubMed
PubMed Central
Google Scholar
Tian L, Qiang T, Liang C et al (2021) RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem 213:113201. https://doi.org/10.1016/j.ejmech.2021.113201
Article
CAS
PubMed
PubMed Central
Google Scholar
Tobaiqy M, Qashqary M, Al-Dahery S et al (2020) Therapeutic management of patients with COVID-19: a systematic review. Infect Prev Pract 2:100061. https://doi.org/10.1016/j.infpip.2020.100061
Article
CAS
PubMed
PubMed Central
Google Scholar
Toots M, Plemper RK (2020) Next-generation direct-acting influenza therapeutics. Transl Res 220:33–42. https://doi.org/10.1016/j.trsl.2020.01.005
Article
CAS
PubMed
PubMed Central
Google Scholar
Toots M, Yoon J-J, Cox RM et al (2019) Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 11:eaax5866. https://doi.org/10.1126/scitranslmed.aax5866
Toots M, Yoon J-J, Hart M et al (2020) Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res 218:16–28. https://doi.org/10.1016/j.trsl.2019.12.002
Article
PubMed
Google Scholar
Urakova N, Kuznetsova V, Crossman DK et al (2018) β-D-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 92:e01965-17
Article
PubMed
PubMed Central
Google Scholar
Vangeel L, Chiu W, De Jonghe S et al (2022) Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 198:105252. https://doi.org/10.1016/j.antiviral.2022.105252
Article
CAS
PubMed
PubMed Central
Google Scholar
Wahl A, Gralinski LE, Johnson CE et al (2021) SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591:451–457. https://doi.org/10.1038/s41586-021-03312-w
Article
CAS
PubMed
PubMed Central
ADS
Google Scholar
Wang B, Li R, Lu Z, Huang Y (2020) Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (albany NY) 12:6049
Article
CAS
Google Scholar
Wikipedia contributors Molnupiravir --- {Wikipedia}{,} The Free Encyclopedia. Wikipedia, Free Encycl
Yoon J-J, Toots M, Lee S et al (2018) Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00766-18
Article
PubMed
PubMed Central
Google Scholar
Zhai P, Ding Y, Wu X et al (2020) The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 55:105955. https://doi.org/10.1016/j.ijantimicag.2020.105955
Article
CAS
PubMed
PubMed Central
Google Scholar
Zumla A, Chan JFW, Azhar EI et al (2016) Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15:327–347
Article
CAS
PubMed
PubMed Central
Google Scholar
(2021) Merck and Ridgeback Biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral therapeutic for the treatment of mild-to-moderate covid-19. Merck